| Autor: |
Björeland, Ulrika, Notstam, Kristina, Fransson, Per, Söderkvist, Karin, Beckman, Lars, Jonsson, Joakim, Nyholm, Tufve, Widmark, Anders, Thellenberg-Karlsson, Camilla |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Radiation oncology (London, England). 18(1) |
| ISSN: |
1748-717X |
| Popis: |
Background Perirectal spacers may be beneficial to reduce rectal side effects from radiotherapy (RT). Here, we present the impact of a hyaluronic acid (HA) perirectal spacer on rectal dose as well as spacer stability, long-term gastrointestinal (GI) and genitourinary (GU) toxicity and patient-reported outcome (PRO). Methods In this phase II study 81 patients with low- and intermediate-risk prostate cancer received transrectal injections with HA before external beam RT (78 Gy in 39 fractions). The HA spacer was evaluated with MRI four times; before (MR0) and after HA-injection (MR1), at the middle (MR2) and at the end (MR3) of RT. GI and GU toxicity was assessed by physician for up to five years according to the RTOG scale. PROs were collected using the Swedish National Prostate Cancer Registry and Prostate cancer symptom scale questionnaires. Results There was a significant reduction in rectal V70% (54.6 Gy) and V90% (70.2 Gy) between MR0 and MR1, as well as between MR0 to MR2 and MR3. From MR1 to MR2/MR3, HA thickness decreased with 28%/32% and CTV-rectum space with 19%/17% in the middle level. The cumulative late grade ≥ 2 GI toxicity at 5 years was 5% and the proportion of PRO moderate or severe overall bowel problems at 5 years follow-up was 12%. Cumulative late grade ≥ 2 GU toxicity at 5 years was 12% and moderate or severe overall urinary problems at 5 years were 10%. Conclusion We show that the HA spacer reduced rectal dose and long-term toxicity. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink